These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33188862)

  • 1. Trends in Radiation Therapy for Bone Metastases, 2015 to 2017: Choosing Wisely in the Era of Complex Radiation.
    Santos PMG; Lapen K; Zhang Z; Lobaugh S; Tsai CJ; Yang TJ; Bekelman JE; Gillespie EF
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):923-931. PubMed ID: 33188862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
    Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
    Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
    Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort.
    Pielkenrood BJ; van der Velden JM; van der Linden YM; Bartels MMT; Kasperts N; Verhoeff JJC; Eppinga WSC; Gal R; Verlaan JJ; Verkooijen HML
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):358-367. PubMed ID: 33333200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of characteristics associated with higher-value radiotherapy episodes of care for bone metastases in Medicare fee-for-service beneficiaries.
    Marshall D; Aldridge MD; Dharmarajan K
    BMJ Open; 2021 Oct; 11(10):e049009. PubMed ID: 34667003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
    Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
    Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.
    de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF
    Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.
    Gill BS; Lin JF; Krivak TC; Sukumvanich P; Laskey RA; Ross MS; Lesnock JL; Beriwal S
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1083-90. PubMed ID: 25216857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Quality Improvement Participation Among US Radiation Oncology Facilities: Compliance with Guideline-Concordant Palliative Radiation Therapy for Bone Metastases.
    Dinh TT; Ford E; Halasz LM; Lee CI
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):564-571. PubMed ID: 32407931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications.
    Roberts KB; Soulos PR; Herrin J; Yu JB; Long JB; Dostaler E; Gross CP
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1186-92. PubMed ID: 23182396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Statewide Practice Pattern Assessment of the Palliative Treatment of Bone Metastasis.
    Spratt DE; Mancini BR; Hayman JA; Boike T; Pierce LJ; Moran JM; Dominello MM; Fireman M; Griffith K; Jolly S;
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):462-467. PubMed ID: 29726364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
    Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study.
    Makita K; Hamamoto Y; Kanzaki H; Kataoka M; Yamamoto S; Nagasaki K; Ishikawa H; Takata N; Tsuruoka S; Uwatsu K; Kido T
    Radiat Oncol; 2021 Nov; 16(1):225. PubMed ID: 34801042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
    Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
    Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-irradiation for painful bone metastases using stereotactic body radiotherapy.
    Ogawa H; Ito K; Shimizuguchi T; Furuya T; Nihei K; Karasawa K
    Acta Oncol; 2018 Dec; 57(12):1700-1704. PubMed ID: 30280622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
    Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
    Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumferential or sectored beam arrangements for stereotactic body radiation therapy (SBRT) of primary lung tumors: effect on target and normal-structure dose-volume metrics.
    Rosenberg MW; Kato CM; Carson KM; Matsunaga NM; Arao RF; Doss EJ; McCracken CL; Meng LZ; Chen Y; Laub WU; Fuss M; Tanyi JA
    Med Dosim; 2013; 38(4):407-12. PubMed ID: 23810414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
    Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
    Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
    Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
    J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.